Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options for an aggregate 98,000 common shares to four newly hired employees on June 25, 2026. The awards were made under the 2023 Employment Inducement Incentive Award Plan in line with Nasdaq Listing Rule 5635(c)(4).
The options have a $36.29 exercise price, a 10-year term, and vest over four years: 25% after one year and the remaining 75% in equal monthly installments over three years, subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) announced that its Board of Directors has elected Yujiro S. Hata as Chairman of the Board, effective June 17, 2026. Hata also serves as President, Chief Executive Officer and director. Terry Rosen, Ph.D., will serve as Lead Independent Director.
IDEAYA is described as a leading precision medicine oncology company with an extensive clinical pipeline and ongoing commercial launch preparations. Hata, who founded IDEAYA over a decade ago, emphasized advancing cancer research and delivering breakthrough therapies for patients with high unmet medical needs.
IDEAYA Biosciences (NASDAQ: IDYA) enrolled the first patient in a Phase 1/2 trial of IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, combined with IDE397 (MAT2A inhibitor) in MTAP-deleted solid tumors, focusing on pancreatic and non-small cell lung cancer.
IDE892 showed favorable CYP450 properties, multiple cleared dose cohorts with no maximum tolerated dose reached, and monotherapy expansion is anticipated in Q3 2026. IDEAYA also announced a Roche collaboration and a third MTAP-deleted program targeting CDKN2A.
IDEAYA Biosciences (Nasdaq: IDYA) closed an underwritten public offering of 7,222,225 common shares at $27.00 and pre-funded warrants for 5,555,576 shares at $26.9999 per warrant. Underwriters fully exercised their option for 1,666,669 extra shares, generating approximately $345 million in gross proceeds.
IDEAYA Biosciences (Nasdaq: IDYA) priced an underwritten public offering of common stock and pre-funded warrants. The company will sell 5,555,556 shares and pre-funded warrants for 5,555,576 shares at $27.00 and $26.9999, respectively, to raise approximately $300 million in gross proceeds.
The offering, including a 30-day option for underwriters to buy up to 1,666,669 additional shares, is expected to close on or about June 10, 2026, subject to customary conditions.
IDEAYA Biosciences (Nasdaq: IDYA) announced a proposed underwritten public offering of up to $300 million in common stock and pre-funded warrants. The company also plans to grant underwriters a 30-day option to buy up to $45 million of additional common shares.
The securities will be issued under an automatically effective shelf registration statement on Form S-3, with J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor as joint book-running managers.
IDEAYA Biosciences (NASDAQ: IDYA) announced a clinical collaboration with Roche to study IDE892, a Phase 1 MTA-cooperative PRMT5 inhibitor, with Roche’s pan-RAS inhibitor RG6505 in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma (PDAC).
IDEAYA will sponsor the trial; Roche supplies RG6505. Both companies retain commercial rights and oversee joint governance, with potential to add IDE397, IDEAYA’s MAT2A inhibitor, as a triplet regimen.
IDEAYA Biosciences (Nasdaq: IDYA) and Servier reported complete Phase 2/3 OptimUM-02 data for the darovasertib + crizotinib combination in first-line HLA*A2:01 negative metastatic uveal melanoma.
The regimen significantly improved median PFS, ORR and DCR versus investigator’s choice, showed a manageable safety profile, and is under FDA RTOR review with NDA completion targeted in H2 2026.
IDEAYA Biosciences (NASDAQ: IDYA) granted non-qualified stock options to purchase an aggregate of 221,000 shares of common stock to six newly hired employees on May 28, 2026. The awards were made under the 2023 Employment Inducement Incentive Award Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $29.34, matching the Nasdaq Global Select Market closing price on the grant date, a 10-year term, and vest over four years, subject to continued service.
IDEAYA Biosciences (NASDAQ: IDYA) will participate in the 2026 Jefferies Global Healthcare Conference in early June 2026. The company’s President and CEO, Yujiro S. Hata, will join a fireside chat and an AI panel, both accessible via webcast on IDEAYA’s investor website.